DICYCLOMINE HYDROCHLORIDE

Post-LOE

dicyclomine hydrochloride

Teva

ANDAINJECTIONINJECTABLE

Approved

Nov 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DICYCLOMINE HYDROCHLORIDE (dicyclomine hydrochloride) by Teva is tract. Approved for functional bowel/irritable bowel syndrome ( ). First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

tract. Animal studies indicate that this action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine ( in vitro , guinea pig ileum); and a direct effect upon smooth muscle…

Indications (1)

functional bowel/irritable bowel syndrome ( )

Worked on DICYCLOMINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.